Press Release
Business

Beta-lactam and Beta-lactamase Inhibitors Market 2019-2028 Key Player, Demand, Growth, Opportunities and Forecast

A new market research report on the Global Beta-lactam and Beta-lactamase Inhibitors market has introduced by KD Market Insights. The report is dedicated to in-depth industry analysis of the global Beta-lactam and Beta-lactamase Inhibitors market. The Global Beta-lactam and Beta-lactamase Inhibitors  analysis is broken down on different segmentation levels including Market By Drug Class, By Disease, By Route of Administration.

The global beta-lactam and beta-lactamase inhibitors market size was $27,126 million in 2018, and is projected to reach $34,170 million by 2028, growing at a CAGR of 2.3% from 2019 to 2028. Beta-lactam and beta-lactamase inhibitors is a most important type of antibacterial agent used for fighting bacterial infections. In addition, these are used to kill or prevent the growth of microorganisms. Based on the molecular structure, beta-lactam and beta-lactamase inhibitors are drug classified into penicillin, cephalosporin, carbapenem, monobactam, and combination.

Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/5464
 
There is an increase in the demand for beta-lactam and beta-lactamase inhibitors, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections and many clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The global beta-lactam and beta-lactamase inhibitors market is segmented based on drug class, disease, route of administration, and region. Based on the drug class, the market is classified into penicillin, cephalosporin, carbapenem, monobactam, and combination. Combination segment is further categorized into penicillin/beta lactamase inhibitors, cephalosporins/beta lactamase inhibitors, and carbapenems/beta lactamase inhibitors. Depending on the disease segment, the market is divided into urinary tract infection (excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), nosocomial pneumonia, blood stream infection, and other diseases. Nosocomial pneumonia segment is further divided into hospital acquired pneumonia, ventilator associated pneumonia, and other nosocomial pneumonia. Based on route of administration, the market is classified into oral, intravenous, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
– This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
– An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
– A comprehensive analysis of the factors that drive and restrain the growth of the global beta-lactam and beta-lactamase inhibitors market is provided.
– An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Drug Class
– Penicillin
– Cephalosporin
– Carbapenem
– Monobactam
– Combination
– – – Penicillin/Beta Lactamase Inhibitors
– – – Cephalosporins/Beta Lactamase Inhibitors
– – – Carbapenems/Beta Lactamase Inhibitors

By Disease
– Urinary Tract Infection (excluding cUTI)
– Respiratory Infection
– Skin Infection
– Complicated Urinary Tract Infection (cUTI)
– Complicated Intra-Abdominal Infections (cIAI)
– Nosocomial Pneumonia
– – – Hospital Acquired Pneumonia
– – – Ventilator Associated Pneumonia
– – – Other Nosocomial Pneumonia
– Blood Stream Infection
– Other Diseases

By Route of Administration
– Oral
– Intravenous
– Others

By Region
North America
– U.S.
– Canada
– Mexico
Europe
– Germany
– France
– Spain
– Italy
– UK
– Rest of Europe
Asia-Pacific
– Japan
– India
– China
– South Korea
– Thailand
– Taiwan
– Vietnam
– Rest of Asia-Pacific
LAMEA
– Brazil
– Saudi Arabia
– South Africa
– Rest of LAMEA

KEY MARKET PLAYERS
– Abbott Laboratories
– Allergan Plc.
– F. Hoffmann-La Roche Ltd.
– GlaxoSmithKline plc
– Merck & Co. Inc.
– Mylan N.V.
– Novartis International AG (Sandoz)
– Pfizer Inc.
– Sanofi
– Teva Pharmaceutical Industries Ltd.

Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/beta-lactam-and-beta-lactamase-inhibitors-market-amr

Table of Content

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary
2.1.1. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Top Winning Strategies
3.3.1. Top Player Positioning, 2018
3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increased Consumption In Low And Middle-Income Countries (Lmics)
3.5.1.2. Rise In Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches For New Beta-Lactam And Beta-Lactamase Inhibitors For Treating Bacterial Infections
3.5.2. Restraints
3.5.2.1. Development of Beta-Lactam Resistance
3.5.2.2. Longer Approval Time By The Regulatory Bodies
3.5.3. Opportunity
3.5.3.1. Discovery of Advanced Prospect Molecules And Novel Combination Therapies To Treat Antibiotic-Resistant Microbial Infections
3.6. Antimicrobial Resistance And Countermeasure Trends
3.6.1. Countermeasure Trends

Chapter 4: Beta-Lactam And Beta Lactamase Inhibitors Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Penicillin
4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Cephalosporin
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Carbapenem
4.4.1. Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5. Monobactam
4.5.1. Key Market Trends And Growth Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country
4.6. Combination
4.6.1. Key Market Trends And Growth Opportunities
4.6.2. Market Size And Forecast, By Type
4.6.2.1. Penicillin/Beta Lactamase Inhibitors
4.6.2.1.1. Market Size And Forecast
4.6.2.2. Cephalosporins/Beta Lactamase Inhibitors
4.6.2.2.1. Market Size And Forecast
4.6.2.3. Carbapenems/Beta Lactamase Inhibitors
4.6.2.3.1. Market Size And Forecast
4.6.3. Market Size And Forecast, By Region
4.6.4. Market Analysis, By Country

Chapter 5: Beta-Lactam And Beta Lactamase Inhibitors Market, By Disease
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Urinary Tract Infection (Excluding Cuti)
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Respiratory Infection
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.4. Skin Infection
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country
5.5. Complicated Urinary Tract Infection (Cuti)
5.5.1. Market Size And Forecast, By Region
5.5.2. Market Analysis, By Country
5.5.3. Number of Patients, By Country
5.6. Complicated Intra-Abdominal Infections (Ciai)
5.6.1. Market Size And Forecast, By Region
5.6.2. Market Analysis, By Country
5.6.3. Number of Patients, By Country
5.7. Nosocomial Pneumonia
5.7.1. Market Size And Forecast, By Type
5.7.1.1. Hospital Acquired Pneumonia
5.7.1.1.1. Market Size And Forecast
5.7.1.2. Ventilator Associated Pneumonia
5.7.1.2.1. Market Size And Forecast
5.7.1.3. Other Nosocomial Pneumonia
5.7.1.3.1. Market Size And Forecast
5.7.2. Market Size And Forecast, By Region
5.7.3. Market Analysis, By Country
5.7.4. Number of Patients, By Country
5.8. Blood Stream Infection
5.8.1. Market Size And Forecast, By Region
5.8.2. Market Analysis, By Country
5.8.3. Number of Patients, By Country

Continue @…
 
Check for Discount @ https://www.kdmarketinsights.com/discount/5464
 
About Us:
 
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
 
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: [email protected]
Website: www.kdmarketinsights.com
https://marketreserachtab.blogspot.com/
http://kdmarketinsights.blogspot.com/